Literature DB >> 25862640

Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett's Esophagus in a Rat Model.

Yukie Kohata1, Kenichi Nakahara, Tetsuya Tanigawa, Hirokazu Yamagami, Masatsugu Shiba, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Tetsuo Arakawa.   

Abstract

BACKGROUND: Barrett's esophagus (BE) is characterized by a distinct Th2-predominant cytokine profile. However, antigens that shift the immune response toward the Th2 profile are unknown. AIM: We examined the effects of rebamipide on the esophageal microbiome and BE development in a rat model.
METHODS: BE was induced by esophagojejunostomy in 8-week-old male Wistar rats. Rats were divided into control and rebamipide-treated group receiving either a normal or a 0.225 % rebamipide-containing diet, respectively, and killed 8, 16, 24, and 32 weeks after the operation. PCR-amplified 16S rDNAs extracted from esophageal samples were examined by terminal-restriction fragment length polymorphism (T-RFLP) analysis to assess microbiome composition. The dynamics of four bacterial genera (Lactobacillus, Clostridium, Streptococcus, and Enterococcus) were analyzed by real-time PCR.
RESULTS: The incidences of BE in the control and rebamipide group at 24 and 32 weeks were 80 and 100, and 20 and 33 %, respectively. T-RFLP analysis of normal esophagus revealed that the proportion of Clostridium was 8.3 %, while that of Lactobacillales was 71.8 %. The proportions of Clostridium increased and that of Lactobacillales decreased at 8 weeks in both groups. Such changes were consistently observed in the control but not in the rebamipide group. Clostridium and Lactobacillus expression was lower and higher, respectively, in the rebamipide group than in the control group.
CONCLUSIONS: Rebamipide reduced BE development and altered the esophageal microbiome composition, which might play a role in BE development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25862640     DOI: 10.1007/s10620-015-3662-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorpholine.

Authors:  M Pera; A Cardesa; J A Bombi; H Ernst; C Pera; U Mohr
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

2.  Esophagitis produced by reflux of duodenal contents in rats.

Authors:  M LEVRAT; R LAMBERT; G KIRSHBAUM
Journal:  Am J Dig Dis       Date:  1962-06

3.  Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants.

Authors:  R C Fitzgerald; B A Onwuegbusi; M Bajaj-Elliott; I T Saeed; W R Burnham; M J G Farthing
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 4.  Inflammation and Barrett's carcinogenesis.

Authors:  A Poehlmann; D Kuester; P Malfertheiner; T Guenther; A Roessner
Journal:  Pathol Res Pract       Date:  2012-04-27       Impact factor: 3.250

5.  Real-time PCR quantitation of clostridia in feces of autistic children.

Authors:  Yuli Song; Chengxu Liu; Sydney M Finegold
Journal:  Appl Environ Microbiol       Date:  2004-11       Impact factor: 4.792

6.  Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality?

Authors:  K L Blackett; S S Siddhi; S Cleary; H Steed; M H Miller; S Macfarlane; G T Macfarlane; J F Dillon
Journal:  Aliment Pharmacol Ther       Date:  2013-04-22       Impact factor: 8.171

7.  Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome.

Authors:  Liying Yang; Xiaohua Lu; Carlos W Nossa; Fritz Francois; Richard M Peek; Zhiheng Pei
Journal:  Gastroenterology       Date:  2009-04-23       Impact factor: 22.682

8.  Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus.

Authors:  Katerina Dvorakova; Claire M Payne; Lois Ramsey; Hana Holubec; Richard Sampliner; Jessica Dominguez; Bohuslav Dvorak; Harris Bernstein; Carol Bernstein; Anil Prasad; Ronnie Fass; Haiyan Cui; Harinder Garewal
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

Review 9.  Toll-like receptors in esophageal cancer.

Authors:  Joonas H Kauppila; Katri S Selander
Journal:  Front Immunol       Date:  2014-05-07       Impact factor: 7.561

10.  Squamous tissue lymphocytes in the esophagus of controls and patients with reflux esophagitis and Barrett's esophagus are characterized by a non-inflammatory phenotype.

Authors:  Alexandra Lind; Leo Koenderman; Johannes G Kusters; Peter D Siersema
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more
  4 in total

1.  Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma.

Authors:  Akinari Sawada; Yasuhiro Fujiwara; Yasuaki Nagami; Fumio Tanaka; Hirokazu Yamagami; Tetsuya Tanigawa; Masatsugu Shiba; Kazunari Tominaga; Toshio Watanabe; Min Gi; Hideki Wanibuchi; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2016-07-26       Impact factor: 3.199

2.  Administration of Non-Absorbable Antibiotics to Pregnant Mice to Perturb the Maternal Gut Microbiota Is Associated with Alterations in Offspring Behavior.

Authors:  Shiro Tochitani; Takahiro Ikeno; Tatsuhito Ito; Asuka Sakurai; Tomoki Yamauchi; Hideo Matsuzaki
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

Review 3.  Human Microbiota in Esophageal Adenocarcinoma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Implications.

Authors:  Wanyue Dan; Lihua Peng; Bin Yan; Zhengpeng Li; Fei Pan
Journal:  Front Microbiol       Date:  2022-01-14       Impact factor: 5.640

4.  Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review.

Authors:  Victor D Plat; Tessel M van Rossen; Freek Daams; Nanne K de Boer; Tim G J de Meij; Andries E Budding; Christina M J E Vandenbroucke-Grauls; Donald L van der Peet
Journal:  Dis Esophagus       Date:  2022-08-13       Impact factor: 2.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.